Randomized trial shows DOACs reduce stroke risk by 69% in atrial fibrillation patients — Evidence Review

A large randomized trial suggests that direct oral anticoagulants (DOACs) can significantly lower the risk of stroke and related complications in people with atrial fibrillation at intermediate stroke risk, without increasing major bleeding. Related research largely supports these findings, indicating DOACs are effective and safe for stroke prevention in atrial fibrillation.

• Multiple large-scale meta-analyses and cohort studies confirm that DOACs reduce stroke risk and major bleeding compared to traditional vitamin K antagonists, with some agents (notably apixaban) showing particularly favorable safety profiles 2 3 6 8 9 10 11 12.
• The new trial expands evidence to intermediate-risk patients, a group previously lacking robust randomized data, whereas earlier studies primarily focused on high-risk individuals or indirect comparisons 2 3 11.
• Some variation exists in bleeding risks and mortality among different DOACs, but overall, the literature demonstrates consistent net clinical benefit for DOACs over warfarin or no anticoagulation in atrial fibrillation populations 2 3 6 8 9 10 11 12.

Study Overview and Key Findings

The SINGLE-AF trial addresses an important clinical uncertainty: whether blood thinners are beneficial for people with atrial fibrillation (AF) who fall into an intermediate stroke risk category, where guidelines have been less decisive. Previous evidence for this population came mainly from observational data or studies of older anticoagulants, leaving clinicians uncertain about the optimal approach. By providing the first randomized, controlled evidence for DOAC use in this group, the study may influence future guidelines and clinical practice, particularly in regions where policy and reimbursement for intermediate-risk patients is still debated.

Property	Value
Study Year	2026
Organization	Yonsei University
Journal Name	New England Journal of Medicine
Authors	Daehoon Kim, Young Soo Lee, Jaemin Shim, Hee Tae Yu, Junbeom Park, Jin-Kyu Park, Il-Young Oh, Ki-Woon Kang, Eue-Keun Choi, Kyoung-Min Park, Hyoung-Seob Park, Dae-Hyeok Kim, Hyung Wook Park, Jun Kim, Jum-Suk Ko, Dongmin Kim, Jong-Youn Kim, Jin-Bae Kim, Jung-Hoon Sung, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Boyoung Joung
Population	People with atrial fibrillation and intermediate stroke risk
Sample Size	n=1803
Methods	Randomized Controlled Trial (RCT)
Outcome	Stroke, systemic embolism, major bleeding, cardiovascular death
Results	DOACs reduced stroke risk by 69% without increasing major bleeding

Literature Review: Related Studies

To contextualize the new findings, we searched the Consensus research database (over 200 million papers) using targeted queries. The following search queries were used:

1. DOACs atrial fibrillation stroke risk
2. blood thinners major bleeding outcomes
3. anticoagulants efficacy safety comparison

Below is a summary of key topics and findings from the related literature:

Topic	Key Findings
How effective and safe are DOACs versus warfarin or no anticoagulation for stroke prevention in atrial fibrillation?	- DOACs are effective in reducing stroke risk in atrial fibrillation, generally outperforming warfarin and with lower or comparable rates of major bleeding 2 3 6 8 11 12 13. - Apixaban, among DOACs, shows the most favorable balance of efficacy and safety, with lower risks of major and intracranial bleeding than warfarin 2 3 8 9 10.
What are the differences in bleeding risk among various anticoagulants?	- Compared to vitamin K antagonists, DOACs are associated with lower risks of major, fatal, and intracranial bleeding, though some (e.g., rivaroxaban) may carry higher risks of gastrointestinal bleeding 6 8 9 11 12. - Real-world and trial data indicate apixaban carries the lowest major bleeding risk among DOACs 8 9 10.
How do DOACs perform in specific patient subgroups or clinical scenarios?	- DOACs remain effective and safe in elderly patients, those with prior stroke, and in the early period after cerebral ischemia, with reduced intracranial bleeding compared to warfarin 3 5 8 12 13. - Even after ischemic stroke despite anticoagulation, patients are at high risk of recurrence, indicating ongoing need for improved strategies 4.
How do alternative approaches (e.g., left atrial appendage closure) compare to DOACs?	- Left atrial appendage closure is noninferior to DOACs for preventing major cardiovascular and bleeding events in high-risk atrial fibrillation 1.

How effective and safe are DOACs versus warfarin or no anticoagulation for stroke prevention in atrial fibrillation?

The SINGLE-AF trial's finding that DOACs substantially reduce stroke and related complications in intermediate-risk AF patients aligns with a robust body of evidence showing that DOACs are effective for stroke prevention and generally safer than warfarin. Prior studies and meta-analyses have consistently demonstrated the efficacy of DOACs across various AF populations, with certain agents (notably apixaban) repeatedly ranking as both the most effective and safest option.

• DOACs reduce the risk of stroke and systemic embolism compared to warfarin, with meta-analyses showing significant relative risk reductions and lower mortality 2 3 11.
• Apixaban is frequently identified as the most effective and cost-effective DOAC, with the lowest rates of major bleeding 2 8 9 10.
• The safety and efficacy of DOACs are consistent across randomized trials and real-world studies, strengthening the external validity of these findings 2 3 9 12 13.
• The new study adds direct randomized evidence for the intermediate-risk group, extending the benefit of DOACs beyond high-risk patients 2 3.

What are the differences in bleeding risk among various anticoagulants?

Bleeding risk remains a critical consideration in anticoagulation therapy. The literature indicates that DOACs, as a class, are associated with lower rates of major, fatal, and intracranial bleeding compared to vitamin K antagonists, though some differences exist among individual DOACs. Notably, apixaban consistently demonstrates the lowest risk of major bleeding, while rivaroxaban may be associated with increased gastrointestinal bleeding compared to warfarin.

• Meta-analyses and cohort studies consistently report that DOACs lower risks of major and intracranial bleeding compared to warfarin 6 8 9 11 12.
• Apixaban stands out with significantly lower risks of both major and intracranial bleeding, and lower fatal bleeding rates 8 9 10.
• Rivaroxaban and dabigatran may carry higher risks of gastrointestinal bleeding, highlighting the need for individualized therapy 9 11 12.
• The new trial found no increase in major bleeding with DOACs in intermediate-risk patients, supporting the overall safety profile observed in broader studies 2 3 6 8 12.

How do DOACs perform in specific patient subgroups or clinical scenarios?

The effectiveness and safety of DOACs are generally preserved across a wide range of patient subgroups, including the elderly, those with prior stroke, and those with recent cerebral ischemia. However, patients who experience ischemic strokes despite anticoagulation remain at high risk for recurrence, suggesting that additional preventive strategies may be needed in such scenarios.

• DOACs are effective and safe in elderly patients, patients with prior strokes, and those with impaired renal function, with particularly strong data for apixaban 3 5 8 12 13.
• Early initiation of DOACs after recent ischemic stroke is associated with reduced risk of poor outcomes, mainly due to lower intracranial bleeding 5.
• Patients who have a stroke despite being on anticoagulation are at high risk for another stroke, emphasizing ongoing clinical challenges 4.
• The new study demonstrates benefit in an intermediate-risk group, which may overlap with some of these patient subpopulations 2 3 5 8.

How do alternative approaches (e.g., left atrial appendage closure) compare to DOACs?

Left atrial appendage closure (LAAC) has emerged as a nonpharmacological alternative to anticoagulation for stroke prevention in AF. In high-risk patients, LAAC has been shown to be noninferior to DOACs for preventing major cardiovascular, neurological, and bleeding events, providing an option for those who cannot tolerate long-term anticoagulation.

• In a randomized trial, LAAC was noninferior to DOACs for prevention of major events in high-risk AF patients 1.
• The choice between LAAC and DOACs may depend on individual patient circumstances, comorbidities, and bleeding risk 1 2.
• While LAAC offers an alternative, the robust evidence base and favorable safety of DOACs support their ongoing use as first-line therapy in most AF patients 2 3 6.
• The SINGLE-AF trial focuses on a population less likely to be considered for LAAC, reinforcing the central role of pharmacological anticoagulation in intermediate-risk groups 1 2.

Future Research Questions

While the SINGLE-AF trial provides important new evidence, several questions remain about optimal anticoagulation strategies in atrial fibrillation, particularly for patients at intermediate risk or with special circumstances. Further research is needed to clarify long-term outcomes, refine patient selection, and compare pharmacologic and nonpharmacologic therapies.

Research Question	Relevance
What are the long-term outcomes of DOAC therapy in intermediate-risk atrial fibrillation patients?	Long-term data on clinical benefits and risks are needed to inform guidelines, since most studies, including SINGLE-AF, have median follow-up of only 1–2 years 2 3.
Are certain DOACs (e.g., apixaban vs. rivaroxaban) preferable for intermediate-risk patients?	Head-to-head trials are lacking; real-world and meta-analytic data suggest differences in safety and efficacy between DOACs, warranting further comparative studies 2 8 9 10.
How should anticoagulation be managed after ischemic stroke despite DOAC therapy?	Patients who have strokes despite anticoagulation are at higher risk for recurrence, and optimal management strategies are not well defined 4.
What is the cost-effectiveness of DOACs in intermediate-risk patients?	While DOACs are cost-effective in high-risk populations, economic analyses specific to intermediate-risk groups can help guide policy and reimbursement 2.
How do nonpharmacological approaches (e.g., left atrial appendage closure) compare with DOACs in intermediate-risk patients?	Comparative trials in intermediate-risk populations are lacking; most current data focus on high-risk groups, leaving a gap in evidence for alternative strategies 1.